TScan Therapeutics (TCRX) AI Stock Analysis

• Market Cap: $80.92M
• Dividend Yield: N/A
• Average Volume (3M): 809.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.53
• Revenue Growth: -70.15%
• EPS Growth: N/A
• Country: US
• Employees: 200
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 52,314,037
• 10 Day Avg. Volume: 927,228
• 30 Day Avg. Volume: 809,398
• PEG Ratio: -0.02
• Price to Book (P/B): 0.37
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.53
• Enterprise Value/Market Cap: 2.90
• Enterprise Value/Revenue: 8.14
• Enterprise Value/Gross Profit: 90.40
• Enterprise Value/Ebitda: -0.53
• 1Y Price Target: $8.80
• Price Target Upside: 498.64% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 48 Neutral
• Price Target: $1.50 ▲(2.04%Upside)

TCRX's overall stock score is mainly influenced by its financial challenges, including weak profitability and cash flow issues. Technical analysis suggests potential stabilization, but valuation remains a concern due to negative earnings. Strategic improvements are necessary to enhance financial health and investor confidence.

Positive Factors

Clinical Trial Data

The TSC-100/101 treatment arm showed a significantly lower relapse rate of 8% compared to 33% in the control arm, suggesting strong efficacy.

Financial Stability

The company ended with $252M in cash, supporting operations well into the future.

Negative Factors

Leadership Changes

Management acknowledged the departure of Peter Marks at CBER was a big loss for the agency.

Market Environment

The valuation framework is being adjusted to reflect a more risk-averse market environment.

TScan Therapeutics Business Overview & Revenue Model

Company Description

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

TScan Therapeutics generates revenue primarily through strategic collaborations, research and development partnerships, and potentially future product sales. The company partners with other pharmaceutical and biotech firms to advance its technology and therapies, often receiving milestone payments, research funding, and royalties as part of these agreements. Additionally, TScan may secure funding through grants and government programs aimed at supporting innovative cancer treatments. As its product candidates advance through clinical trials and potentially reach commercialization, the company anticipates generating revenue from the sale of its TCR-T cell therapies.

TScan Therapeutics Financial Statement Overview

Summary

TScan Therapeutics shows potential with a solid cash position and equity base, but faces significant challenges in revenue generation, profitability, and cash flow management. The income statement reflects declining revenue trends and significant losses, while the balance sheet is moderately stable but burdened by high debt levels. Cash flow remains consistently negative, highlighting operational inefficiencies.

Income Statement

The income statement shows a declining revenue trend with significant negative net income and margins over the years. Despite a slight revenue growth in recent periods, the company continues to operate at a substantial loss, indicating weak profitability and a need for strategic improvements.

Balance Sheet

The balance sheet is moderately stable, showing a positive equity position and substantial cash reserves. However, the company has high debt levels, resulting in a challenging debt-to-equity ratio. The equity ratio remains healthy, but the company needs to manage its liabilities more effectively to improve financial stability.

Cash Flow

Cash flow analysis reveals a consistent negative free cash flow, indicating operational challenges. While the company has managed substantial financing cash inflows, it struggles with operating cash flow, requiring better cash management and operational efficiency to enhance financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.42M	2.82M	21.05M	13.54M	10.14M	1.08M
Gross Profit	2.59M	2.82M	-67.10M	8.40M	6.81M	-19.49M
EBITDA	-128.06M	-119.74M	-80.10M	-59.91M	-45.30M	-25.00M
Net Income	-131.48M	-127.50M	-89.22M	-65.81M	-48.63M	-26.02M
Balance Sheet
Total Assets	332.71M	371.12M	272.15M	199.09M	188.11M	49.74M
Cash, Cash Equivalents and Short-Term Investments	251.69M	290.11M	192.04M	120.03M	161.41M	34.79M
Total Debt	97.04M	97.38M	92.43M	85.98M	6.04M	7.43M
Total Liabilities	122.51M	130.15M	121.28M	99.66M	27.33M	92.20M
Stockholders Equity	210.20M	240.97M	150.87M	99.43M	160.78M	-42.46M
Cash Flow
Free Cash Flow	-123.79M	-114.65M	-64.50M	-70.73M	-58.62M	-7.26M
Operating Cash Flow	-119.14M	-110.82M	-61.36M	-66.50M	-48.68M	-3.02M
Investing Cash Flow	-75.25M	-52.61M	-60.76M	-4.22M	-9.94M	-4.24M
Financing Cash Flow	207.98M	208.76M	135.44M	29.36M	189.67M	288.00K

TScan Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.47
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCRX, the sentiment is Negative. The current price of 1.47 is below the 20-day moving average (MA) of 1.57, below the 50-day MA of 1.50, and below the 200-day MA of 2.88, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 47.84 is Neutral, neither overbought nor oversold. The STOCH value of 17.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TCRX.

TScan Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.55B	0.30	-61.90%	2.27%	17.11%	1.58%
ADAG	49 Neutral	$87.15M	―	-55.14%	―	-99.43%	-69.40%
TCRX	48 Neutral	$80.92M	―	-78.93%	―	-70.15%	―
ADVM	40 Neutral	$47.63M	―	-127.99%	―	―	37.54%
CNTX	37 Underperform	$56.29M	―	-55.59%	―	―	65.02%
RANI	32 Underperform	$29.55M	―	-1372.59%	―	―	20.85%
ELTX	30 Underperform	$123.50M	―	-744.59%	―	―	27.65%

TScan Therapeutics Corporate Events

TScan Therapeutics Elects New Directors at Annual Meeting

On June 30, 2025, TScan Therapeutics held its annual meeting of stockholders, where two key proposals were voted upon. The stockholders elected Stephen Biggar, Gavin MacBeath, and Garry Nicholson as Class I directors for a three-year term and ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (TCRX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on TScan Therapeutics stock, see the TCRX Stock Forecast page.